Overview
Sustainable Strategies for Optimally Integrating FcRn Inhibitors into Individualized Treatment Paradigms for Generalized Myasthenia Gravis (gMG)
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Recent data reveal that patients with gMG treated with older therapies often express negative sentiment towards MG symptoms, particularly fear, and desire treatments that offer symptom control, convenience, and flexibility, highlighting the need for improved therapeutic decision-making. The advent of novel neonatal Fc receptor (FcRn) inhibitors has shifted the treatment paradigm to address these unmet needs, increasing the potential for patients to achieve minimal manifestation status and reducing the burden of disease.
To help you adeptly navigate the complexities of treatment, immerse yourself in this interactive “choose your path” decision tree and supporting practice compendium with expert perspectives to assist with the application of the latest evidence to individualize therapy for this “snowflake” disease.
Do you have questions about how to individualize treatment and when to use FcRn inhibitors? Do you wonder…
- How to recognize patients who are refractory to conventional treatments?
- Does age of disease onset matter? What about patient comorbidities?
- How does disease severity inform first-line therapy and the integration of novel treatments?
- How do factors such as dosing frequency, route of administration, and patient preference weigh on treatment selection?
- How the mechanisms of action of the FcRn inhibitors differ, and how they impact patient QoL?
Start your engaging learning experience now and find the answers to these questions and more!
This activity is intended for neurologists, neuromuscular specialists, and advanced practice providers in the specialty setting.
Generalized myasthenia gravis (gMG) profoundly affects patients' functional capacity and QoL due to muscle weakness and fatigability impacting ocular, bulbar, respiratory, and limb muscles. Patients typically experience persistent physical functioning impairment with ongoing fluctuations in symptoms, leading to substantial effects on emotional, social, and economic well-being. A significant proportion of patients with gMG, ranging from 30-50%, do not achieve satisfactory clinical improvement and stability with standard therapies, underscoring the need for more effective and safer agents. Novel neonatal Fc receptor (FcRn) inhibitors were recently developed to address autoantibodies in a broad gMG population. As such, clinicians must be able to integrate factors such as age of onset, autoantibody profile, clinical manifestation, gender distribution, and thymic pathology to classify MG subtypes and tailor treatment strategies with identification of candidates for FcRn inhibitor therapy.
Upon completion of this activity, learners will be able to:
• Discuss the clinical burden often associated with generalized myasthenia gravis (gMG)
• Appraise the latest clinical trial data supporting the efficacy and safety of new and emerging neonatal Fc receptor (FcRn) inhibitors in patients with gMG
• Integrate FcRn inhibitors into individualized treatment plans for gMG, balancing efficacy, safety, dosing frequency, and patient preferences
• Discuss the clinical burden often associated with generalized myasthenia gravis (gMG)
• Appraise the latest clinical trial data supporting the efficacy and safety of new and emerging neonatal Fc receptor (FcRn) inhibitors in patients with gMG
• Integrate FcRn inhibitors into individualized treatment plans for gMG, balancing efficacy, safety, dosing frequency, and patient preferences
Provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from argenx US, Inc
James F. Howard Jr, MD
Professor, Neurology, Medicine, & Allied Health
University of North Carolina at Chapel Hill School of Medicine
Professor of Neurology
UNC Hospitals
Chapel Hill, NC
Neelam Goyal, MD
Clinical Professor, Neurology and Neurological Sciences
Standford University
Palo Alto, CA
Professor, Neurology, Medicine, & Allied Health
University of North Carolina at Chapel Hill School of Medicine
Professor of Neurology
UNC Hospitals
Chapel Hill, NC
Neelam Goyal, MD
Clinical Professor, Neurology and Neurological Sciences
Standford University
Palo Alto, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
James F. Howard Jr, MD (Faculty)
Advisory Board: Alexion Pharmaceuticals (AstraZeneca), Amgen, argenx, Biologix Pharma, CorEvitas, Curie.bio, Hansa Biopharma, F. Hoffman-Laroche Ltd, Immunovant, Merck EMD Serono, NMD Pharma, Novartis, Ra Pharmaceuticals (UCB), Regeneron Pharmaceuticals, Sanofi US, Seismic Therapeutics, TG Therapeutics, Toleranzia AB, UCB Biosciences, Zai Labs
Consultant: Biohaven Ltd, Cartesian Therapeutics
Research/Grant Support: Ad Scientiam, Alexion Pharmaceuticals (AstraZeneca), argenx, Cartesian Therapeutics, Millennium Pharmaceuticals, PCORI, NMD Pharma, Ra Pharmaceuticals (UCB), UCB Biosciences
Neelam Goyal, MD (Faculty)
Advisory Board: argenx, Alexion, Amgen, Dianthus, EMD Serono, Janssen, UCB
Grants/Research Support: argenx
The following financial relationships have been provided:
James F. Howard Jr, MD (Faculty)
Advisory Board: Alexion Pharmaceuticals (AstraZeneca), Amgen, argenx, Biologix Pharma, CorEvitas, Curie.bio, Hansa Biopharma, F. Hoffman-Laroche Ltd, Immunovant, Merck EMD Serono, NMD Pharma, Novartis, Ra Pharmaceuticals (UCB), Regeneron Pharmaceuticals, Sanofi US, Seismic Therapeutics, TG Therapeutics, Toleranzia AB, UCB Biosciences, Zai Labs
Consultant: Biohaven Ltd, Cartesian Therapeutics
Research/Grant Support: Ad Scientiam, Alexion Pharmaceuticals (AstraZeneca), argenx, Cartesian Therapeutics, Millennium Pharmaceuticals, PCORI, NMD Pharma, Ra Pharmaceuticals (UCB), UCB Biosciences
Neelam Goyal, MD (Faculty)
Advisory Board: argenx, Alexion, Amgen, Dianthus, EMD Serono, Janssen, UCB
Grants/Research Support: argenx
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: intravenous or subcutaneous immunoglobulin, plasma exchange, rituximab, corticosteroids, and other immunosuppressive agents such as azathioprine, mycophenolate mofetil, and cyclosporin
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: intravenous or subcutaneous immunoglobulin, plasma exchange, rituximab, corticosteroids, and other immunosuppressive agents such as azathioprine, mycophenolate mofetil, and cyclosporin
This activity will take approximately 90 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
